Media coverage about Editas Medicine (NASDAQ:EDIT) has been trending somewhat positive on Sunday, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Editas Medicine earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.7900641078236 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern’s analysis:
- Form 8-K Editas Medicine, Inc. For: Sep 18 – StreetInsider.com (streetinsider.com)
- Brokerages Anticipate Editas Medicine, Inc. (EDIT) Will Announce Earnings of -$0.61 Per Share (americanbankingnews.com)
- Genome Editing Market – Industrial Forecast on Global Industry Analysis and Trends Till 2025 (sbwire.com)
- Trending Hot Stock’s Analysis – Editas Medicine, Inc. (NASDAQ:EDIT) – The Investor Guide (wallstreetnews24.com)
Shares of Editas Medicine (EDIT) opened at 22.85 on Friday. The firm’s market capitalization is $935.16 million. The firm’s 50-day moving average price is $20.92 and its 200 day moving average price is $20.92. Editas Medicine has a 52 week low of $12.43 and a 52 week high of $28.50.
Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Wednesday, August 9th. The company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). The business had revenue of $3.10 million during the quarter, compared to analyst estimates of $2.20 million. Editas Medicine had a negative return on equity of 67.75% and a negative net margin of 2,091.36%. The business’s quarterly revenue was down 8.8% on a year-over-year basis. During the same period last year, the business earned ($0.54) EPS. On average, analysts anticipate that Editas Medicine will post ($2.88) EPS for the current year.
EDIT has been the topic of several recent analyst reports. Zacks Investment Research upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Wednesday, July 12th. SunTrust Banks, Inc. initiated coverage on Editas Medicine in a research report on Thursday, July 13th. They set a “hold” rating and a $17.00 target price on the stock. J P Morgan Chase & Co set a $27.00 target price on Editas Medicine and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Cann reiterated a “hold” rating on shares of Editas Medicine in a research report on Thursday, August 10th. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Editas Medicine in a research report on Tuesday, July 18th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Editas Medicine currently has an average rating of “Buy” and a consensus target price of $25.52.
In related news, insider Katrine Bosley sold 16,666 shares of Editas Medicine stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $20.33, for a total transaction of $338,819.78. Following the completion of the sale, the insider now owns 1,414,629 shares of the company’s stock, valued at $28,759,407.57. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last three months, insiders have sold 43,332 shares of company stock valued at $876,673.
Editas Medicine Company Profile
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.